Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim–Chester disease

References

• Chester W. Über lipoidgranulomatose. Virchows Arch Pathol Anat Physiol Klin Med 1930; 279:561-602; http://dx.doi.org/10.1007/BF01942684
   Google Scholar
• Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, Wechsler J, Brun B, Remy M, Wallaert B, Petit H, Grimaldi A, Wechsler B et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 1996; 75:157-69; PMID:8965684; http://dx.doi.org/10.1097/00005792-199605000-00005
   PubMed Web of Science ®Google Scholar
• Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol 2012; 24:53-9; PMID:22089098; http://dx.doi.org/10.1097/BOR.0b013e32834d861d
   PubMed Web of Science ®Google Scholar
• Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 2013; 72:1691-5; PMID:23396641; http://dx.doi.org/10.1136/annrheumdis-2012-202542
   PubMed Web of Science ®Google Scholar
• Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014; 124:483-926; PMID:24850756; http://dx.doi.org/10.1182/blood-2014-03-561381
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L. Erdheim-Chester disease. Eur J Intern Med. 2015; 26:223-9; PMID:25865950; http://dx.doi.org/10.1016/j.ejim.2015.03.004
   PubMed Web of Science ®Google Scholar
• Stoppacciaro A, Ferrarini M, Salmaggi C, Colarossi C, Praderio L, Tresoldi M, Beretta AA, Sabbadini MG. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum 2006; 54:4018-22; PMID:17133532; http://dx.doi.org/10.1002/art.22280
   PubMed Web of Science ®Google Scholar
• Arnaud L, Gorochov G, Charlotte F, Lvovschi V, Parizot C, Larsen M, Ghillani-Dalbin P, Hervier B, Kahn JE, Deback C et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011; 117:2783-90; PMID:21205927; http://dx.doi.org/10.1182/blood-2010-10-313510
   PubMed Web of Science ®Google Scholar
• Haroche J, Charlotte F, Arnaud L, von Deimling A, Hélias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay D, Lesot A, Mokhtari K et al. High prevalence of BRAFV600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120:2700-3; PMID:22879539; http://dx.doi.org/10.1182/blood-2012-05-430140
   PubMed Web of Science ®Google Scholar
• Cangi MG, Biavasco R, Cavalli G, Grassini G, Dal-Cin E, Campochiaro C, Guglielmi B, Berti A, Lampasona V, von Deimling A et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis 2015; 74:1596-602; PMID:24671772; http://dx.doi.org/10.1136/annrheumdis-2013-204924
   PubMed Web of Science ®Google Scholar
• Blombery P, Wong SQ, Lade S, Prince HM. Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol 2012; 30:e331-2; PMID:23008323; http://dx.doi.org/10.1200/JCO.2012.43.2260
   PubMed Web of Science ®Google Scholar
• Cavalli G, Biavasco R, Borgiani B, Dagna L. Oncogene-induced senescence as a new mechanism of disease: the paradigm of Erdheim-Chester disease. Front Immunol 2014; 5:281; PMID:24982657; http://dx.doi.org/10.3389/fimmu.2014.00281
   PubMed Web of Science ®Google Scholar
• Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F, Le Toquin S, Bensadoun H, Larousserie F, Silvera S et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010; 116:4070-6; PMID:20724540; http://dx.doi.org/10.1182/blood-2010-04-279240
   PubMed Web of Science ®Google Scholar
• Dagna L, Corti A, Langheim S, Guglielmi B, De Cobelli F, Doglioni C, Fragasso G, Sabbadini MG, Ferrarini M. Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol 2012; 30:e286-90; PMID:22869874; http://dx.doi.org/10.1200/JCO.2012.41.9911
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013; 121:1495-500; PMID:23258922; http://dx.doi.org/10.1182/blood-2012-07-446286
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Tolédano D, Barete S, Charlotte F, Cluzel P, Donadieu J et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol 2015; 33:411-8; PMID:25422482; http://dx.doi.org/10.1200/JCO.2014.57.1950
   PubMed Web of Science ®Google Scholar
• Puimège L, Libert C, Van Hauwermeiren F. Regulation and dysregulation of tumor necrosis factor receptor-1. Cytokine Growth Factor Rev 2014; 25:285-300; PMID:24746195; http://dx.doi.org/10.1016/j.cytogfr.2014.03.004
   PubMed Web of Science ®Google Scholar
• Sciola V, Massironi S, Conte D, Caprioli F, Ferrero S, Ciafardini C, Peracchi M, Bardella MT, Piodi L. Plasma chromogranin a in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:867-71; PMID:19090560; http://dx.doi.org/10.1002/ibd.20851
   PubMed Web of Science ®Google Scholar
• Di Comite G, Rossi CM, Marinosci A, Lolmede K, Baldissera E, Aiello P, Mueller RB, Herrmann M, Voll RE, Rovere-Querini P et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-α-elicited endothelial activation. J Leukoc Biol 2009; 85:81-7; PMID:18832606; http://dx.doi.org/10.1189/jlb.0608358
   PubMed Web of Science ®Google Scholar
• Gregorc V, Spreafico A, Floriani I, Colombo B, Ludovini V, Pistola L, Bellezza G, Vigan∫ MG, Villa E, Corti A. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer. 2007; 110:845-53; PMID:17599769; http://dx.doi.org/10.1002/cncr.22856
   PubMed Web of Science ®Google Scholar
• Corti A, Ferrari R, Ceconi C. Chromogranin A and tumor necrosis factor-α (TNF) in chronic heart failure. Adv Exp Med Biol 2000; 482:351-9; PMID:11192595; http://dx.doi.org/10.1007/0-306-46837-9_28
   PubMed Web of Science ®Google Scholar
• Helle KB, Corti A. Chromogranin A: a paradoxical player in angiogenesis and vascular biology. Cell Mol Life Sci 2015; 72:339-48; PMID:25297920; http://dx.doi.org/10.1007/s00018-014-1750-9
   PubMed Web of Science ®Google Scholar
• Crippa L, Bianco M, Colombo B, Gasparri AM, Ferrero E, Loh YP, Curnis F, Corti A. A new chromogranin A-dependent angiogenic switch activated by thrombin. Blood 2013; 121:392-402; PMID:23190532; http://dx.doi.org/10.1182/blood-2012-05-430314
   PubMed Web of Science ®Google Scholar
• Ferrero E, Scabini S, Magni E, Foglieni C, Belloni D, Colombo B, Curnis F, Villa A, Ferrero ME, Corti A. Chromogranin A protects vessels against tumor necrosis factor α-induced vascular leakage. FASEB J 2004; 18:554-6; PMID:14734634
   PubMed Web of Science ®Google Scholar
• Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 2007; 64:2863-86; PMID:17717629; http://dx.doi.org/10.1007/s00018-007-7254-0
   PubMed Web of Science ®Google Scholar
• Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, Parrinello G, Corti A. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002; 23:967-74; PMID:12069452; http://dx.doi.org/10.1053/euhj.2001.2977
   PubMed Web of Science ®Google Scholar
• Jansson AM, Røsjø H, Omland T, Karlsson T, Hartford M, Flyvbjerg A, Caidahl K. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 2009; 30:25-3; PMID:19028779; http://dx.doi.org/10.1093/eurheartj/ehn513
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Gegenhuber A, Struck J, Poelz W, Langsteger W, Haltmayer M, Mueller T. Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin Chim Acta 2009; 400:91-6; PMID:19000665; http://dx.doi.org/10.1016/j.cca.2008.10.012
   PubMed Web of Science ®Google Scholar
• Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F, Maseri A. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007; 28:1117-27; PMID:17389654; http://dx.doi.org/10.1093/eurheartj/ehm022
   PubMed Web of Science ®Google Scholar
• Haroche J, Amoura Z, Dion E, Wechsler B, Costedoat-Chalumeau N, Cacoub P, Isnard R, Généreau T, Wechsler J, Weber N et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore). 2004; 83:371-92; PMID:15525849
   PubMedGoogle Scholar
• Berti A, Ferrarini M, Ferrero E, Dagna L. Cardiovascular manifestations of Erdheim-Chester disease. Clin Exp Rheumatol 2015; 33(2 Suppl 89):S-155-63; PMID:25738753
   PubMedGoogle Scholar
• Dagna L, Girlanda S, Langheim S, Rizzo N, Bozzolo EP, Sabbadini MG, Ferrarini M. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford) 2010; 49:1203-6; PMID:20097905; http://dx.doi.org/10.1093/rheumatology/kep461
   PubMed Web of Science ®Google Scholar
• Ferrero E, Belloni D, Corti A, Doglioni C, Dagna L, Ferrarini M. TNF-α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. Rheumatology (Oxford) 2014; 53:198-200; PMID:23893523; http://dx.doi.org/10.1093/rheumatology/ket246
   PubMed Web of Science ®Google Scholar
• Tota B, Angelone T, Cerra MC. The surging role of Chromogranin A in cardiovascular homeostasis. Front Chem 2014; 2:64; PMID:25177680; http://dx.doi.org/10.3389/fchem.2014.00064
   PubMed Web of Science ®Google Scholar
• Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L et al. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget 2014; 5:3607-10; PMID:25003820; http://dx.doi.org/10.18632/oncotarget.1964
   PubMed Web of Science ®Google Scholar
• Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov 2015; 5:64-71; PMID:25324352; http://dx.doi.org/10.1158/2159-8290.CD-14-0742
   PubMed Web of Science ®Google Scholar